Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
9.76
-1.24 (-11.27%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Armata Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 358 | 229 | 67 | 117 | 45 | 148 | |
| Market Cap Growth | 993.06% | 241.56% | -42.84% | 161.30% | -69.80% | 165.90% | |
| Enterprise Value | 637 | 392 | 190 | 207 | 59 | 149 | |
| Last Close Price | 9.76 | 6.28 | 1.85 | 3.24 | 1.24 | 5.48 | |
| PS Ratio | 72.91 | 46.62 | 12.94 | 25.86 | 8.14 | 33.18 | |
| PB Ratio | - | -1.05 | -1.39 | -3.65 | 1.24 | 5.85 | |
| P/TBV Ratio | - | - | - | - | 1.38 | 6.78 | |
| EV/Sales Ratio | 129.87 | 79.85 | 36.75 | 45.66 | 10.69 | 33.23 | |
| Debt / Equity Ratio | -1.32 | -1.32 | -2.63 | -3.75 | 1.35 | 1.50 | |
| Net Debt / Equity Ratio | -1.28 | -1.28 | -2.44 | -3.33 | 0.94 | 1.09 | |
| Net Debt / EBITDA Ratio | -9.41 | -9.41 | -2.85 | -2.68 | -0.94 | -1.22 | |
| Net Debt / FCF Ratio | -10.62 | -10.62 | -2.97 | -1.92 | -0.98 | -1.11 | |
| Asset Turnover | 0.06 | 0.06 | 0.06 | 0.05 | 0.07 | 0.08 | |
| Quick Ratio | 1.02 | 1.02 | 0.21 | 1.03 | 0.94 | 2.76 | |
| Current Ratio | 1.19 | 1.19 | 0.23 | 1.16 | 1.09 | 3.12 | |
| Return on Equity (ROE) | - | - | - | -3439.35% | -120.10% | -104.65% | |
| Return on Assets (ROA) | -23.90% | -23.90% | -28.70% | -26.32% | -27.89% | -27.25% | |
| Return on Capital Employed (ROCE) | -46.00% | -46.00% | -111.10% | -49.90% | -52.10% | -36.70% | |
| Earnings Yield | -48.61% | -76.02% | -28.26% | -58.95% | -82.37% | -15.60% | |
| FCF Yield | -7.36% | -11.51% | -58.90% | -47.45% | -77.40% | -16.76% | |
| Buyback Yield / Dilution | 38.64% | 38.64% | -63.71% | -5.20% | -42.27% | -46.84% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.